Summary of use during lactation
Little information is available on the clinical use of empagliflozin during breastfeeding. Empagliflozin is an uncharged molecule that is 86% protein bound in plasma, so it is unlikely to pass into breastmilk in clinically important amounts. The manufacturer does not recommend empagliflozin during breastfeeding because of a theoretical risk to the infant’s developing kidney. An alternate drug may be preferred, especially while nursing a newborn or preterm infant.
Drug levels in milk and infant serum
Maternal Levels. Relevant published information was not found as of the revision date. Infant Levels. Relevant published information was not found as of the revision date.
Effects in breastfed infants
A mother with glycogen storage disease type Ib was taking empagliflozin 20 mg daily during pregnancy and postpartum. Breastfeeding (extent and duration not stated) was successfully initiated, and the infant showed normal development at 3 months of age.[1]
Effects on lactation and breastmilk
Relevant published information was not found as of the revision date.
Alternative drugs to consider
Acarbose, Glipizide, Glyburide, Insulin, Metformin, Miglitol
Source: Drugs and Lactation Database (LactMed®), National Institute of Child Health and Human Development, NCBI Bookshelf. Check LactMed for the most recent revision.
Medical disclaimer: This page is for qualified healthcare professionals and is a decision-support aid only. It does not replace clinical judgement, local protocols or product information. Verify every dose and threshold before use. See the full Medical Disclaimer.